Item 5.07 Submission of Matters to a Vote of Security Holders.
Decibel Therapeutics, Inc. (the "Company") held its 2023 annual meeting of
stockholders (the "Annual Meeting") on June 13, 2023. The following is a summary
of the matters voted on at the Annual Meeting.
(a)
The stockholders of the Company elected one Class II director, Saraswathy
Nochur, Ph. D., to serve for a three-year term expiring at the 2026 annual
meeting of stockholders and until her successor has been duly elected and
qualified. The results of the stockholders' vote with respect to the election of
the Class II director were as follows:
Name For Withheld Broker Non-Votes
Saraswathy Nochur, Ph.D. 19,531,690 861,542 2,992,978
(b)
The stockholders of the Company approved an amendment to the Company's Restated
Certificate of Incorporation to reflect new Delaware law provisions regarding
officer exculpation (the "Officer Exculpation Amendment"). The results of the
stockholders' vote with respect to such approval were as follows:
For Against Abstain Broker Non-Votes
19,422,896 966,681 3,655 2,992,978
The Company filed a Certificate of Amendment to the Restated Certificate of
Incorporation with the Secretary of State of the State of Delaware on June 13,
2023 to effect the Officer Exculpation Amendment.
(c)
The stockholders of the Company ratified the appointment of Ernst & Young LLP as
the Company's independent registered public accounting firm for the fiscal year
ending December 31, 2023. The results of the stockholders' vote with respect to
such ratification were as follows:
For Against Abstain
22,922,399 276,484 187,327
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
DECIBEL THERAPEUTICS, INC. 
